SCHEMBL6449486

SCHEMBL6449486

CON(Cc1ccccc1OC(C)C)C(=O)/C=C1\OC(C)(C)OC1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 1/20 0.35
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
CRHBP P24387 1/20 0.34
KMT2A Q03164 1/20 0.34
CRHR2 Q13324 1/20 0.34
FFAR4 Q5NUL3 2/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TAS1R3 Q7RTX0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078334 1.00 TSPO (0.35) TSPOALDH1A1KDM4EMEN1CRHBP
SCHEMBL6077318 0.84 SLC1A5 (0.32) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6077321 0.84 SLC1A5 (0.32) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6077281 0.83 KMT2A (0.37) TSPOALDH1A1KDM4EMEN1KMT2A
SCHEMBL6077300 0.83 KMT2A (0.37) TSPOALDH1A1KDM4EMEN1KMT2A
SCHEMBL6077728 0.81 CYP1A2 (0.38) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6077726 0.81 CYP1A2 (0.38) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL6879189 0.80 NPSR1 (0.36) ALDH1A1NPSR1ACHE
SCHEMBL6077514 0.77 ALDH1A1 (0.38) ALDH1A1MEN1KMT2ALMNATDP1
SCHEMBL6077512 0.77 ALDH1A1 (0.38) ALDH1A1MEN1KMT2ALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US disclosed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US disclosed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase ACSS2, ARSA, ASS1 TSPO 3291/4885ALDH1A1 640/4885KDM4E 689/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 TSPO 1822/4885ALDH1A1 976/4885KDM4E 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.